SBI² 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Large pharma companies at SBI² 2026

Nov 2–4, 2026 Boston, MA ~300 attendees Website

6 large pharma companies are at SBI² 2026 — 5 presentations on the program. Most represented: Genentech (2 on the program), Johnson & Johnson (1 on the program), Merck (MSD) (1 on the program). 4 of them have their own page in this guide. As of Nov 2, 2026.

All 60 organizations at SBI² 2026 →

Topic
Showing 1–6 of 6 organizations
OrganizationSBI² 2026 Attendance
Genentech
South San Francisco, CA
Large pharma
Biotechnology company in the Roche group developing medicines for cancer, immune and neurological diseases.
Talk
Mon Nov 2
9:00am–12:00pm
Processing and Evaluating High-Content Morphological Profiles
Practical computing steps that clean noise from image-based cell profiles, and how to check the cleanup keeps real biological differences.
Image analysis, data and AI
Talk
Wed Nov 4
8:30am–9:00am
Toward Interpretable and Predictive Image-Based Screening
Making image-based genetic screens easier to interpret, and testing how well their images predict gene activity.
Phenotypic screening and assays · Multi-omics and spatial profiling
Johnson & Johnson
New Brunswick, NJ
Large pharma
US healthcare company developing medicines and medical technology across oncology, immunology, neuroscience and other areas.
Session
Wed Nov 4
1:30pm–4:15pm
Session 4: Applications: Novel Phenotypes to Decisions
Phenotypic screening and assays · with Arvinas
Merck (MSD)
Rahway, NJ
Large pharma
US pharmaceutical company, known as MSD outside North America, with medicines and vaccines in oncology, infectious disease and other areas.
Spotlight
Wed Nov 4
11:30am–11:45am
Benchmarking Live-Cell Profiling with ChromaLIVE Against Fixed Cell Painting for Early Drug Discovery
Spotlight hosted by Saguaro Biosciences
Phenotypic screening and assays
Novartis
Basel, Switzerland
Large pharma
Swiss pharmaceutical company developing medicines for cardiovascular, cancer, immune and neurological diseases.
Keynote
Tue Nov 3
4:30pm–5:30pm
Drug Discovery: How We Got Here and Where We Might Be Going
How drug discovery has changed over the past three decades, and how recent AI methods apply to its long-standing problems.
Image analysis, data and AI
AbbVie
North Chicago, IL
Large pharma
US pharmaceutical company with medicines in immunology, oncology, neuroscience and aesthetics.
A member sits on SBI²’s 2026 leadership: Secretary
Pfizer
New York, NY
Large pharma
US pharmaceutical company developing medicines and vaccines across oncology, inflammation, infectious disease and other areas.
A member sits on SBI²’s 2026 leadership: Treasurer

Explore the full SBI² 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full SBI² 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from large pharma companies

Tell us what you sell and we’ll find the people at these large pharma companies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse SBI² 2026 by

Exhibit hall

Not affiliated with or endorsed by the Society of Biomolecular Imaging and Informatics. Submit a correction